ClinicalTrials.gg
CompletedNCT02927925Updated Jan 14, 2021Results posted

A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type

A Phase 2 interventional study of Daratumumab in Lymphoma, sponsored by Janssen Research & Development, LLC. Completed at 17 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-14.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Lymphoma by Johnson & Johnson — none open to participants now, 1 under way, none of them phase 3. Lymphoma · Johnson & Johnson.

Enrollment
7th of 10
32 · median 101
Started
2017
the only one that year
Phase 2
3 of 13
none open now
Registered
13th of 13
by date

Among the 13 studies in Lymphoma by Johnson & Johnson, this one is the 7th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2017, is one of 3 in phase 2, and was the 13th registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

None of the 13 studies in Lymphoma by Johnson & Johnson is open now. The open studies under Lymphoma, anywhere →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Lymphoma by Johnson & Johnson as a file.
02

Study summary

The purpose of this study is to assess the clinical efficacy and safety of daratumumab in relapsed or refractory natural killer/T-cell lymphomas (NKTCL).

03

Conditions studied

  • Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented as confirmed extranodal natural killer/T-cell lymphomas (NK/T)-cell lymphoma, nasal type according to the World Health Organization (WHO) classification and the pathology report will be verified by the Sponsor
  • Failed at least 1 and who, according to treating physician or investigator, is not candidate to receive other treatment modalities
  • At least 1 measurable site of disease
  • (ECOG) performance status score of 0, 1 or 2 and greater than or equal to (>=) 3 months

Exclusion criteria

Exclusion Criteria:

  • Received daratumumab or other antiCD38 therapies previously
  • Previous allogenic stem cell transplant or stem cell transplantation within 12 weeks before the first administration of the study drug
  • Clinical symptoms of central nervous system involvement
  • Known , known moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma of any classification
  • cardiac disease, including:Myocardial infarction within 6 months before the first study agent administration, or unstable or uncontrolled disease/condition related to or affecting cardiac function (eg, unstable angina, congestive heart failure, Class III-IV); Uncontrolled cardiac arrhythmia ( [CTCAE] [most recent version] Grade 3 or higher) or clinically significant abnormalities; Screening 12-lead ECG showing a baseline as corrected QTc >470 msec
  • Seropositive for
  • Seropositive for or
  • Abnormal laboratory values according to protocol defined parameters at screening
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Daratumumab

    Participants will receive daratumumab 16 milligram per kilogram (mg/kg) by intravenous (IV) infusion once weekly for 8 weeks, then every 2 weeks for 16 weeks, then every 4 weeks thereafter until study drug discontinuation due to progressive disease (PD), consent withdrawal or unacceptable toxicity.

    Drug: Daratumumab

Interventions

  • Participants will receive daratumumab 16 mg/kg as intravenous infusion.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Overall Response

    Overall response was defined as the percentage of participants who achieved complete response (CR) or partial response (PR) per Revised Criteria for Response Assessment of Hodgkin and non-Hodgkin lymphoma: LUGANO classification based on blinded independent central review (BICR). As per Revised Response Criteria for Malignant Lymphoma, Lymph node measurements were taken from Computed Tomography (CT), CT portion of the Positron Emission Tomography/Computed Tomography (PET/CT), where applicable. CR: complete disappearance of all evidence of disease; PR as a greater than (\>) 50 percent (%) decrease in the sum of the products of the maximal perpendicular diameters of measured lesions (SPD) and no new sites.

    Time frame: Up to 2 years and 11 months

Secondary outcomes

  1. Percentage of Participants With Complete Response (CR)

    CR was defined as the percentage of participants who achieved CR as per Revised Criteria for Response Assessment of Hodgkin and non-Hodgkin lymphoma: LUGANO classification based on BICR. CR was a complete disappearance of all evidence of disease.

    Time frame: Up to 2 years and 11 months

  2. Progression Free Survival (PFS)

    PFS was defined as the duration from the date of the first daratumumab dose to the date of progression/relapse or death, whichever came first. Progressive disease (PD) was defined as any new lesion greater than (\>) 1.5 centimeter (cm) in any axis or greater than or equal to (\>=) 50 percent (%) increase in previously involved sites.

    Time frame: Up to 2 years and 11 months

  3. Duration of Response (DoR)

    DoR was defined as duration from the date of the initial documentation of a response to the date of first documented evidence of progressive disease (PD) (or relapse for participants who experienced CR). PD was defined as any new lesion \>1.5 cm in any axis or \>= 50% increase in previously involved sites.

    Time frame: Up to 2 years and 11 months

  4. Time to Response

    Time to response was defined as the duration from the date of the first dose of daratumumab to the earliest date that a response (CR/PR based on BICR) is first documented. CR was defined as complete disappearance of all evidence of disease; PR as a greater than (\>) 50 percent (%) decrease in the sum of the products of the maximal perpendicular diameters of measured lesions (SPD) and no new sites.

    Time frame: Up to 2 years and 11 months

  5. Overall Survival (OS)

    OS was defined as the duration from the date of the first daratumumab dose to the date of death.

    Time frame: Up to 2 years and 11 months

  6. Number of Participants With Treatment Emergent Adverse Events (TEAE) as a Measure of Safety and Tolerability

    An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAE were defined as AEs with onset during the treatment period or that are a consequence of a pre-existing condition that has worsened since baseline.

    Time frame: Up to 2 years and 11 months

  7. Number of Participants With Clinically Significant Change in Vital Signs

    Number of participants with clinically significant change in vital signs (blood pressure, temperature, pulse rate, and weight) was reported.

    Time frame: Up to 2 years and 11 months

  8. Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities

    Number of participants with clinically significant ECG abnormalities were reported.

    Time frame: Up to 2 years and 11 months

  9. Number of Participants With Clinically Significant Change in Physical Finding

    Number of participants with clinically significant change in physical finding was reported.

    Time frame: Up to 2 years and 11 months

  10. Number of Participants With Clinically Significant Change in Laboratory Parameters

    Number of participants with clinically significant change in hematology (WBC, hemoglobin, platelets, neutrophils, and lymphocytes) and biochemistry (alanine transaminase \[ALT\], aspartate transaminase \[AST\], sodium, potassium, bilirubin, alkaline phosphatase, calcium laboratory parameters were reported.

    Time frame: Up to 2 years and 11 months

07

Results

Posted Jan 14, 2021

Participant flow

Participant flow — Overall Study
MilestoneDaratumumab
Started32
Completed0
Not completed32
Withdrew: Death16
Withdrew: Physician decision1
Withdrew: Withdrawal by subject11
Withdrew: Other3
Withdrew: Disease progression at clinical cutoff1

Outcome measures

PrimaryPercentage of Participants With Overall Response

Overall response was defined as the percentage of participants who achieved complete response (CR) or partial response (PR) per Revised Criteria for Response Assessment of Hodgkin and non-Hodgkin lymphoma: LUGANO classification based on blinded independent central review (BICR). As per Revised Response Criteria for Malignant Lymphoma, Lymph node measurements were taken from Computed Tomography (CT), CT portion of the Positron Emission Tomography/Computed Tomography (PET/CT), where applicable. CR: complete disappearance of all evidence of disease; PR as a greater than (\>) 50 percent (%) decrease in the sum of the products of the maximal perpendicular diameters of measured lesions (SPD) and no new sites.

Time frame:
Up to 2 years and 11 months
Reported as:
Number · percentage of participants
Percentage of Participants With Overall Response
percentage of participantsDaratumumab
Percentage of Participants With Overall Response25.0 (11.5 to 43.4)
SecondaryPercentage of Participants With Complete Response (CR)

CR was defined as the percentage of participants who achieved CR as per Revised Criteria for Response Assessment of Hodgkin and non-Hodgkin lymphoma: LUGANO classification based on BICR. CR was a complete disappearance of all evidence of disease.

Time frame:
Up to 2 years and 11 months
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Response (CR)
percentage of participantsDaratumumab
Percentage of Participants With Complete Response (CR)3.1 (0.08 to 16.22)
SecondaryProgression Free Survival (PFS)

PFS was defined as the duration from the date of the first daratumumab dose to the date of progression/relapse or death, whichever came first. Progressive disease (PD) was defined as any new lesion greater than (\>) 1.5 centimeter (cm) in any axis or greater than or equal to (\>=) 50 percent (%) increase in previously involved sites.

Time frame:
Up to 2 years and 11 months
Reported as:
Median · days
Progression Free Survival (PFS)
daysDaratumumab
Progression Free Survival (PFS)53.0 (43.0 to 106.0)
SecondaryDuration of Response (DoR)

DoR was defined as duration from the date of the initial documentation of a response to the date of first documented evidence of progressive disease (PD) (or relapse for participants who experienced CR). PD was defined as any new lesion \>1.5 cm in any axis or \>= 50% increase in previously involved sites.

Time frame:
Up to 2 years and 11 months
Reported as:
Median · days
Duration of Response (DoR)
daysDaratumumab
Duration of Response (DoR)55.0 (29.0 to 339.0)
SecondaryTime to Response

Time to response was defined as the duration from the date of the first dose of daratumumab to the earliest date that a response (CR/PR based on BICR) is first documented. CR was defined as complete disappearance of all evidence of disease; PR as a greater than (\>) 50 percent (%) decrease in the sum of the products of the maximal perpendicular diameters of measured lesions (SPD) and no new sites.

Time frame:
Up to 2 years and 11 months
Reported as:
Median · days
Time to Response
daysDaratumumab
Time to Response52.0 (49 to 57)
SecondaryOverall Survival (OS)

OS was defined as the duration from the date of the first daratumumab dose to the date of death.

Time frame:
Up to 2 years and 11 months
Reported as:
Median · days
Overall Survival (OS)
daysDaratumumab
Overall Survival (OS)141.0 (94.0 to 235.0)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAE) as a Measure of Safety and Tolerability

An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAE were defined as AEs with onset during the treatment period or that are a consequence of a pre-existing condition that has worsened since baseline.

Time frame:
Up to 2 years and 11 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAE) as a Measure of Safety and Tolerability
ParticipantsDaratumumab
Number of Participants With Treatment Emergent Adverse Events (TEAE) as a Measure of Safety and Tolerability26
SecondaryNumber of Participants With Clinically Significant Change in Vital Signs

Number of participants with clinically significant change in vital signs (blood pressure, temperature, pulse rate, and weight) was reported.

Time frame:
Up to 2 years and 11 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change in Vital Signs
ParticipantsDaratumumab
Number of Participants With Clinically Significant Change in Vital Signs0
SecondaryNumber of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities

Number of participants with clinically significant ECG abnormalities were reported.

Time frame:
Up to 2 years and 11 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities
ParticipantsDaratumumab
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities2
SecondaryNumber of Participants With Clinically Significant Change in Physical Finding

Number of participants with clinically significant change in physical finding was reported.

Time frame:
Up to 2 years and 11 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change in Physical Finding
ParticipantsDaratumumab
Number of Participants With Clinically Significant Change in Physical Finding0
SecondaryNumber of Participants With Clinically Significant Change in Laboratory Parameters

Number of participants with clinically significant change in hematology (WBC, hemoglobin, platelets, neutrophils, and lymphocytes) and biochemistry (alanine transaminase \[ALT\], aspartate transaminase \[AST\], sodium, potassium, bilirubin, alkaline phosphatase, calcium laboratory parameters were reported.

Time frame:
Up to 2 years and 11 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change in Laboratory Parameters
ParticipantsDaratumumab
Hematology: WBC0
Hematology: Hemoglobin0
Hematology: Platelets0
Hematology: Neutrophils0
Hematology: Lymphocytes0
Chemistry: ALT0
Chemistry: AST0
Chemistry: Sodium0
Chemistry: Potassium0
Chemistry: Bilirubin0
Chemistry: Alkaline phosphatase0
Chemistry: Calcium0

Adverse events

Collected over Up to 2 years and 11 months. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Daratumumab21/32 (65.6%)17/32 (53.1%)31/32 (96.9%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventDaratumumab
PyrexiaGeneral disorders5/32
ThrombocytopeniaBlood and lymphatic system disorders3/32
Septic ShockInfections and infestations3/32
Febrile NeutropeniaBlood and lymphatic system disorders2/32
CellulitisInfections and infestations2/32
PneumoniaInfections and infestations2/32
EpistaxisRespiratory, thoracic and mediastinal disorders2/32
NeutropeniaBlood and lymphatic system disorders1/32
Periorbital SwellingEye disorders1/32
UveitisEye disorders1/32
Most frequent other events
Showing 10 of 142
Most frequent other events
EventDaratumumab
PyrexiaGeneral disorders20/32
AnaemiaBlood and lymphatic system disorders9/32
ThrombocytopeniaBlood and lymphatic system disorders9/32
Alanine Aminotransferase IncreasedInvestigations9/32
ChillsGeneral disorders8/32
Aspartate Aminotransferase IncreasedInvestigations8/32
HeadacheNervous system disorders8/32
LeukopeniaBlood and lymphatic system disorders7/32
NeutropeniaBlood and lymphatic system disorders7/32
FatigueGeneral disorders7/32

Baseline characteristics

All treated analysis set included all the participants who have received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Daratumumab
Mean54.8 ± 14
Sex: Female, Male
Sex: Female, Male(Participants)Daratumumab
Female9
Male23
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Daratumumab
Hispanic or Latino0
Not Hispanic or Latino32
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Daratumumab
American Indian or Alaska Native0
Asian32
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Daratumumab
CHINA7
HONG KONG1
REPUBLIC OF KOREA17
SINGAPORE2
TAIWAN, PROVINCE OF CHINA5
08

Study locations

17 sites
  • Cancer Hospital, Chinese Academy of Medical Sciences
    Beijing, 100021, China
  • Beijing Cancer Hospital
    Beijing, 100142, China
  • Sun Yat-Sen University Cancer Center
    Guangzhou, 510060, China
  • 1st Affiliated Hospital of Zhejiang University Medical College
    Hangzhou, 310003, China
  • Ruijin Hospital, Shanghai Jiao Tong University
    Shanghai, 200025, China
  • Queen Mary Hospital, University of Hong Kong
    Hong Kong, Hong Kong
  • National Cancer Center
    Goyang-si, 10408, Korea, Republic of
  • Severance Hospital
    Seoul, 03722, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • Seoul St. Mary's Hospital
    Seoul, 06591, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 3080, Korea, Republic of
  • Asan Medical Center
    Seoul, 5505, Korea, Republic of
  • Singapore General Hospital
    Singapore, 169608, Singapore
  • National Cancer Centre Singapore
    Singapore, 169610, Singapore
  • Changhua Christian Hospital
    Changhua, 50006, Taiwan
  • China Medical University Hospital
    Taichung, 40447, Taiwan
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan
09

References and documents

Publications

  • Huang H, Zhu J, Yao M, Kim TM, Yoon DH, Cho SG, Eom HS, Lim ST, Yeh SP, Song Y, Kwong YL, Kim JS, Jin J, Shi Y, Kim H, Qing M, Zhou T, Gao G, Dong Z, Qi M, Kim WS. Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study. J Hematol Oncol. 2021 Feb 15;14(1):25. doi: 10.1186/s13045-020-01020-y. PubMed 33588922 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Jan 2020, 34 months.

Results were first posted in Jan 2021, 1 year after primary completion.

Of 56 industry-sponsored phase 2 interventional studies under Lymphoma, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's 34 months is close to that.

Counting every sponsor, half of 293 studies reached it within 61 months; a quarter within 36 and three quarters within 105.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2016
First posted
Oct 7, 2016
StartActual
Feb 14, 2017
Primary completionActual
Jan 2, 2020
CompletionActual
Jan 7, 2020
Results first posted
Jan 14, 2021
Last update
Jan 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02927925
Responsible party
Sponsor
First posted
Oct 7, 2016
Start date
Feb 14, 2017
Primary completion
Jan 2, 2020
Completion
Jan 7, 2020
Results posted
Jan 14, 2021
Last update
Jan 14, 2021

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daratumumab

Start the discussion